One To Watch

Theriva Biologics

A clinical-stage immuno-oncology company developing systemically delivered oncolytic viruses designed to penetrate solid-tumor defenses and amplify the impact of standard cancer treatments.

Company Overview

Theriva Bio develops therapeutic candidates that target biological barriers to effective treatment. In oncology, the company’s core thesis is that solid tumors protect themselves through physical stroma and immune-suppressive microenvironments that limit drug access and blunt immune responses. Its lead program is designed to replicate selectively within tumors, disrupt stromal shielding and create a setting where chemotherapy and immuno-oncology approaches may work better.

Beyond oncology, Theriva retains enzyme-based programs intended to reduce gastrointestinal harm from commonly used therapies, with a focus on preventing downstream complications driven by microbiome disruption and intestinal injury.

Headquarters and Global Presence

Theriva Bio is based in Rockville, Maryland, and operates with a footprint typical of a small, development-stage biotech: a US corporate base, an EU presence tied to clinical and regulatory activity, and clinical execution through external trial networks in specialty oncology centers.

Founding and History

Theriva’s current identity reflects a repositioning from its earlier corporate form as Synthetic Biologics. The company rebranded to align more explicitly with its immuno-oncology direction and oncolytic virus platform strategy. Its oncology programs stem from work associated with adenovirus engineering and systemic delivery concepts intended to expand the reach of oncolytic virotherapy beyond intratumoral administration.

Therapy Areas and Focus

Theriva’s focus areas are:

oncology, centered on hard-to-treat solid tumors where stromal barriers and immune suppression are clinically relevant
supportive and GI-protective programs intended to reduce treatment-related microbiome damage and intestinal injury in high-risk settings

Technology Platforms and Modalities

Theriva’s lead platform is oncolytic adenovirus therapy designed for intravenous administration and tumor-selective replication.

Key elements of the approach include:

systemic delivery intended to reach metastatic disease sites
tumor selectivity to concentrate viral replication within malignant tissue
stromal degradation as a mechanism to improve penetration and reshape the tumor microenvironment
combination positioning, most prominently with standard chemotherapy in pancreatic cancer

Non-oncology assets are enzyme-based oral approaches designed to act locally in the GI tract to reduce collateral damage from systemic therapies.

Key Personnel

Steven Shallcross, chief executive officer, chief financial officer and director
Jeffrey J. Kraws, chairman
Manel Cascallo, senior leadership role supporting EU operations
Ramon Alemany, scientific originator associated with the company’s adenovirus technology base

Strategic Partnerships

Theriva’s operating model is designed to support partnering at pivotal decision points, particularly in oncology where late-stage trials and commercialization require scale. In practice, its partnership logic is typically based on:

co-development and funding support for registrational programs
regional commercialization structures in specialist oncology markets
manufacturing and supply collaboration where viral-vector scale-up is a gating factor

FAQ Section

Theriva Bio is a clinical-stage company focused on oncolytic virus immuno-oncology, with an emphasis on systemic delivery and tumor microenvironment disruption. Its lead priority is demonstrating that an intravenously administered oncolytic adenovirus can generate clinically meaningful benefit in solid tumors when combined with standard therapy.

The lead program is VCN-01, a tumor-selective oncolytic adenovirus designed to replicate within tumor cells and degrade stromal barriers that can limit drug penetration and immune activity. The program is positioned for combination use, particularly with chemotherapy, in indications where stromal protection is a major feature of disease biology.

Theriva’s primary near-term focus is metastatic pancreatic ductal adenocarcinoma. The company also references additional oncology opportunities where systemic oncolytic virotherapy and stromal disruption could be relevant, while maintaining select GI-protective programs outside oncology.

Theriva’s disclosed pipeline typically includes:

VCN-01 for solid tumors, with development emphasis in pancreatic cancer and other selected settings
SYN-004 (ribaxamase), an oral enzyme intended to degrade certain IV beta-lactam antibiotics in the GI tract to reduce microbiome injury and related complications
SYN-020, an oral recombinant intestinal alkaline phosphatase program intended to address GI and systemic inflammatory consequences linked to intestinal dysfunction

The central considerations are whether systemic administration can reliably deliver sufficient tumor exposure, whether stromal disruption translates into better outcomes in combination regimens, and whether the safety profile supports repeated dosing. The practical bar for differentiation is clear benefit over chemotherapy alone in a setting where incremental gains are clinically meaningful.

Clinical progression typically follows Phase I safety and dosing confirmation, Phase II signal and regimen definition, and Phase III confirmation in a well-controlled, multinational trial structure.

Theriva’s positioning emphasizes intravenous delivery for metastatic reach and a mechanistic focus on stromal degradation as an enabling step for combination benefit. Differentiation is less about “virus versus no virus” and more about whether the platform can reproducibly open the tumor environment to standard therapies in a way that is measurable, scalable and clinically durable.

The most decision-relevant milestones are execution-driven:

selection and locking of a registrational-grade Phase III design for VCN-01 in metastatic pancreatic cancer
consistency of efficacy signals when combined with standard chemotherapy in a defined patient population
confirmation that repeat dosing is practical and tolerable
clarity on partnering and manufacturing readiness as the program approaches pivotal scale

Want to Update your Company's Profile?